Recall Record

Tarrytown, NY, United States

Siemens Healthcare Diagnostics, Inc. recalls

153 recalls recorded since 2018, most recently on 17 August 2026. 86 are listed as ongoing. Status and classification are as published by the FDA.

Recalls153
Ongoing (FDA)86
Terminated or completed67
Class I (FDA)0

Ongoing Class II Medical devices

Recall started
17 August 2026
Reason
The potential for falsely elevated results.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Burkina Faso, Canada, Chile, China, Columbia, Croatia, Cura¿ao, St Eus, Czech Republic, Denmark, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia,
Initiated
Voluntary: Firm initiated
Recall number
Z-3335-2026

Ongoing Class II Medical devices

Recall started
13 July 2026
Reason
Due to unacceptable precision performance exhibited in certain lots of the Emit 2000 Quinidine Assay, which may lead to erroneously elevated quinidine measurements, creating risk of sub-optimal patient treatment, including potential life-threatening cardiac arrhythmias or inadequate antimalarial therapy.
Distribution
Worldwide - US Nationwide distribution in the state of CA and the country of Italy.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2976-2026, Z-2975-2026

Ongoing Class II Medical devices

Recall started
6 July 2026
Reason
Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.
Distribution
Worldwide distribution - US Nationwide including Puerto Rico and the countries of Australia, Austria, Bahamas, Belgium, Brazil, Canada, Chile, Curacao, St. Eus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel,¿Italy,¿Latvia, Malaysia, Netherlands, New Zealand, N
Initiated
Voluntary: Firm initiated
Recall number
Z-2890-2026

Ongoing Class III Medical devices

Recall started
26 June 2026
Reason
out-of-specification sodium azide concentration in Syva Emit Tox Serum Tricyclic Antidepressant Calibrator/Controls Lot U2. While the assay results were not impacted, the overall health risk to lab technicians due to this issue is low, as exposure is limited by small volumes and a 0.2% post-reconstitution sodium azide concentration, with the worst outcome being mild skin or eye irritation and no serious harm anticipated.
Distribution
Worldwide - US Nationwide distribution in the states CA, ID, IL, IN, MA, MS, NC, NM, NY, OH, OK, OR, PA, WA, and Northern Mariana Islands part of USA and the countries of Canada, South Africa, Brazil, Chile, Colombia.
Initiated
Voluntary: Firm initiated
Recall number
Z-2881-2026

Ongoing Class III Medical devices

Recall started
26 June 2026
Reason
Out-of-specification sodium azide concentration in Syva Emit Disopyramide Enzyme Immunoassay Calibrator Lot U1. While the assay results were not impacted, the overall health risk to lab technicians due to this issue is low, as exposure is limited by small volumes and a 0.2% post-reconstitution sodium azide concentration, with the worst outcome being mild skin or eye irritation and no serious harm anticipated.
Distribution
Worldwide - US Nationwide distribution in the states of CA and VA. The country of Japan.
Initiated
Voluntary: Firm initiated
Recall number
Z-2880-2026

Ongoing Class II Medical devices

Recall started
8 June 2026
Reason
The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bangladesh, Bolivia, Brazil, Bulgaria, Burkina¿Faso, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Democratic Republic Congo, Denmark, Ecuador, Egypt, El Salvador, Estonia,
Initiated
Voluntary: Firm initiated
Recall number
Z-2703-2026

Ongoing Class II Medical devices

Recall started
7 May 2026
Reason
A potential positive bias in quality control (QC) and patient sample results in three lots of the Dimension Tacrolimus (TAC) Flex reagent cartridge.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Austria, Brazil, Croatia, Germany, Hungary, India, Italy, Japan, Korea, Lithuania, Pakistan, Poland, Saudi Arabia, Spain, South Africa, Sri Lanka, Turkey, United Arab Emirates.
Initiated
Voluntary: Firm initiated
Recall number
Z-2398-2026

Ongoing Class II Medical devices

Recall started
2 April 2026
Reason
Use of the affected product can result in discrepant low pH and measured Total Carbon Dioxide (mTCO2) results and corresponding calculated values in arterial, venous, and capillary patient samples. An erroneously low pH or mTCO2 reading can lead to inappropriate treatment of nonexistent acidosis (respiratory of metabolic) or missed diagnosis of alkalosis (a true high pH: respiratory or metabolic alkalosis), potentially causing harm through unnecessary interventions with the former or failure to deliver appropriate treatment with the latter.
Distribution
Worldwide distribution - US Nationwide and the countries of Italy, Spain, Austria, Portugal, Ireland, France, Romania, Canada, India, Philippines, Mexico.
Initiated
Voluntary: Firm initiated
Recall number
Z-2005-2026

Ongoing Class II Medical devices

Recall started
18 March 2026
Reason
Siemens Healthcare Diagnostics is recalling certain lots of Dimension Creatinine Flex reagent cartridge (Dimension CRE2) because a potential imprecision in the Dimension CRE2 quality control (QC) and patient sample results using lot numbers GA6307 and BA7005 on the Dimension System. This imprecision may lead to erroneously decreased or increased creatinine patient results
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Brazil, Cambodia, Canada, Chile, China, Columbia, Costa Rica, Ecuador, Egypt, Germany, Honduras, India, Indonesia, Korea, Kuwait, Lebanon, Malaysia, Mexico, Nicaragua, Pakistan, Paraguay, Philippines,
Initiated
Voluntary: Firm initiated
Recall number
Z-1980-2026

Ongoing Class II Medical devices

Recall started
23 February 2026
Reason
A potential for depressed results for Atellica CH A1c_E when processing Atellica CH RCRP on the same analyzer. Customers processing A1c_E and RCRP on separate analyzers are not impacted by the recall. The frequency and magnitude of the negative bias and imprecision increase over time and are not consistent with the assay Instructions For Use (IFU). When this issue is present, Quality Control (QC) results demonstrate a negative trend and increased imprecision. The clinical impact of a negative (A1c_E) bias may lead to a delay in diagnosis for diabetes or lead to less-than-optimal treatment for existing diabetes.
Distribution
Domestic: Nationwide Distribution International: Argentina, Australia, Bangladesh, Brazil, Bulgaria , Canada, Chile, China, Colombia, Croatia , Cura¿ao, St Eus, Czech Republic , Denmark , Ecuador, Egypt , Estonia , Finland , France , Georgia
Initiated
Voluntary: Firm initiated
Recall number
Z-1657-2026

Ongoing Class II Medical devices

Recall started
20 January 2026
Reason
Falsely depressed UAlb patient results may occur. Affected samples with any urine albumin concentration above the UAlb measuring interval >40.0 mg/dL may report values between 6.2 mg/dL and 40.0 mg/dL.
Distribution
Worldwide distribution - US Nationwide and the countries of Australia, Austria, Belgium, Brazil, Canada, Chile, Curacao,¿St¿Eus, Czech¿Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Korea, Latvia, Malaysia, Netherlands, New Zealand, Norway, Portugal, Romania,
Initiated
Voluntary: Firm initiated
Recall number
Z-1484-2026

Ongoing Class II Medical devices

Recall started
6 October 2025
Reason
The barcode orientation on affected devices causes incorrect scanning order of tubes within the allergen holder wedge. When using an IMMULITE 2000 / IMMULITE 2000 XPi instrument in combination with a Zebra barcode scanner, the instrument will not correctly recognize the position of tubes within the allergen holder wedge.
Distribution
Worldwide - US Nationwide distribution in the state of CA and the countries of Argentina, Australia, Austria, Belgium, Bosnia Herzeg. , Brazil, Canary Islands, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Estonia, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Latvia
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0493-2026, Z-0492-2026, Z-0491-2026

Ongoing Class II Medical devices

Recall started
22 September 2025
Reason
The potential for falsely depressed Intact PTH patient results at the low end of the assay range, less than or equal to 50 pg/mL (less than or equal to 5.3 pmol/L), when using specific lots identified by the firm on the IMMULITE 2000/IMMULITE 2000 XPi systems. The bias is observed in both serum and plasma samples.
Distribution
Worldwide - US Nationwide distribution in the states of AL, CA, DC, FL, ID, IN, LA, MD, NC, NJ, NY, PA, SC and the countries of Argentina, Australia, Bolivia, Bosnia Herzeg, Brazil, Bulgaria, Canada, Chile, Colombia, Cyprus, Czech Republic, Ecuador, Egypt, France, Germany, Greece, Guatemala, Hondura
Initiated
Voluntary: Firm initiated
Recall number
Z-0366-2026

Ongoing Class II Medical devices

Recall started
11 August 2025
Reason
Potential for falsely depressed patient, quality control (QC), and/or calibration results or delayed results.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Denmark, Egypt, Estonia, Ethiopia, Finland, France, Georgia, Germany, Greece,
Initiated
Voluntary: Firm initiated
Recall number
Z-2542-2025

Ongoing Class II Medical devices

Recall started
7 July 2025
Reason
Siemens Healthcare Diagnostics Inc. has confirmed that a negative sodium bias may exist in some epoc test card lots. All other analytes are performing as intended. The observed average bias for sodium was -4.4 mmol/L. The maximum bias observed was -14 mmol/L, which occurred at a higher sodium concentration around 150 mmol/L. No positive bias has been observed. Quality Control (QC) fluid may or may not detect the issue depending on the bias magnitude and the frequency of QC testing.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Austria, Bahrain, Bolivia, Brazil, Canada, Canary Islands, Chile, Croatia, Denmark, Ecuador, Estonia, France, Fren. Polynesia, Germany, Greece, Guatemala, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jordan, Kazakh
Initiated
Voluntary: Firm initiated
Recall number
Z-2272-2025

Ongoing Class II Medical devices

Recall started
26 June 2025
Reason
Siemens Healthcare Diagnostics is recalling the RAPIDPoint 500 Systems Wash/Waste Cartridge Lot WW/08925 due to a manufacturing error causing positive and negative bias in Ionized Calcium, Potassium, pH, Chloride, pCO2, Glucose and Lactate analytes and their derivatives. Four complaints were filed related to this event that led to Siemens Healthcare Diagnostics identifying an error in the manufacturing process and initiated corrective actions. Use of the affected device may result in errors during QC which could lead to a delay in patient treatment. If bias generated from this issue is not caught during QC erroneous results may cause temporary or medically reversible adverse health consequences to patients.
Distribution
worldwide distribution - US Nationwide and the countries of Canada, Chile, Japan, Paraguay.
Initiated
Voluntary: Firm initiated
Recall number
Z-2230-2025

Ongoing Class II Medical devices

Recall started
4 June 2025
Reason
Products have the incorrect platelet (PLT) value assignments for the ADVIA 120/2120/2120i Hematology Systems.
Distribution
Worldwide distribution - US Nationwide and the countries of AR, AU, BR, CA, CL, CN, CO, CR, HK, ID, IN, JP, KR, MX, MY, PE, PY, SA, SG, TH, TW, UY, VN, & ZA.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2089-2025, Z-2088-2025, Z-2087-2025, Z-2086-2025

Ongoing Class II Medical devices

Recall started
22 May 2025
Reason
Contamination of the diluent by sodium hypochlorite (NaOCl) which may impact calibrator, quality control (QC), and patient results for all assays except for sodium, potassium, and chloride.
Distribution
Worldwide distribution - US Nationwide and the countries of Canada, Bahamas.
Initiated
Voluntary: Firm initiated
Recall number
Z-2027-2025

Ongoing Class II Medical devices

Recall started
15 April 2025
Reason
Certain lots of Atellica IM Homocysteine Calibrator and ADVIA Centaur HCY Calibrator do not meet the assay Instructions for Use (IFU) reference interval due to calibrator instability resulting in increased positive bias.
Distribution
Worldwide - US Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, IA, IL, IN, KY, MA, MD, ME, MI, MO, MT, NC, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, SC, TX, UT, VA, VT, WI, WY and the countries of Austria, Belgium, Croatia, Curacao,¿St¿Eus, Czech¿Republi
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1821-2025, Z-1822-2025

Ongoing Class II Medical devices

Recall started
31 March 2025
Reason
Siemens Healthcare Diagnostics Inc., is recalling their Stratus CS Acute Care cTNI TestPak, an IVD test for cardiac troponin I in heparinized plasma by removal. The reason for the recall is an increased occurrence of random non-repeatable false positive cardiac Troponin l(cTnI) results at any point during the TestPaks shelf life when using the Stratus CS cTnI Acute Care Testpak.
Distribution
Worldwide - US Nationwide distribution in the states of CA, IL, KS, MI, MO, NJ, NY, OH, OK, PA, SC & WI. The countries of Austria, Canada, Chile, France, Germany, Iraq, Italy, Malaysia, North Macedonia, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Switzerland & Vietnam.
Initiated
Voluntary: Firm initiated
Recall number
Z-1673-2025

Ongoing Class II Medical devices

Recall started
19 March 2025
Reason
The occurrence of discrepant high pH results in samples introduced with higher injection volumes with epoc sensor configuration 45.n.
Distribution
Domestic: Nationwide Distribution; Foreign: Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Bolivia, Bosnia, Brazil, Cambodia, Canada, Canary Islands, Chile, China, Colombia, Croatia, Ecuador, Estonia, France, Germany, Ghana, Greece, Guadeloupe, Guatemala, Hong Kong, Hungary, I
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1684-2025, Z-1685-2025

Ongoing Class II Medical devices

Recall started
11 March 2025
Reason
Incorrect software flagging may occur for the assay that may potentially lead to an erroneous result.
Distribution
Domestic: Nationwide Distribution. International: Australia, Austria, Bahamas, Bahrain, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Denmark,¿Estonia, Finland, France, Germany, Greece,¿Hong Kong, Hungary, India, Ireland, Israel, Italy, Korea, Kuwait, La
Initiated
Voluntary: Firm initiated
Recall number
Z-1551-2025

Ongoing Class II Medical devices

Recall started
22 November 2024
Reason
Siemens Healthcare Diagnostics is recalling their epoc Blood Analysis System because of a software malfunction that occurs when specific criteria are met that can result in the incorrect patient name being assigned to a blood measurement by the device if the user of the device does not ensure verification of the correct patient name. The software malfunction has the potential to impact patient safety via misdiagnosis and/or mistreatment by a clinician if the wrong patient information is saved with the test result from the subject device.
Distribution
Nationwide Foreign: Albania Angola Argentina Australia Austria Bahrain Bangladesh Belarus Belgium Bolivia Bosnia and Herzegovina Brazil Cambodia Canada Chile China Colombia Croatia Czech Republic Denmark Ecuador Egypt Estonia Finland France Germany Ghana Greece Guadeloupe Hong Kong Hungary Iceland I
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0736-2025, Z-0741-2025, Z-0739-2025, Z-0734-2025, Z-0737-2025, Z-0738-2025, Z-0735-2025, Z-0740-2025

Ongoing Class II Medical devices

Recall started
12 November 2024
Reason
Siemens Healthcare Diagnostics is recalling two lots of their Dimension Vista¿ Total Magnesium (MG) Flex Reagent Cartridges (lots 24057BB and 24064BC) due to the potential for falsely low measurements of magnesium in plasma. Because the error is intermittent, existing quality control procedures may not recognize that a patients results are incorrect, and the results may be reported out
Distribution
Worldwide distribution - US Nationwide and the countries of Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Slovenia, Spain.
Initiated
Voluntary: Firm initiated
Recall number
Z-0767-2025

Ongoing Class II Medical devices

Recall started
4 November 2024
Reason
Potential that the IMT Diluent volume remaining (% remaining) does not decrease as expected on the Atellica CI Analyzer, potentially leading to the IMT Diluent being empty while still displaying that volume is remaining. In this case Sodium (Na), Potassium (K) and Chloride (Cl) test results may be falsely elevated. Quality Control materials demonstrate the same behavior.
Distribution
Worldwide distribution - US Nationwide and the countries of Austria, Bangladesh, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Ecuador, Egypt, France, Germany, Greece, Hong Kong, Hungary, India, Iraq, Israel, Italy, Japan, Jordan, Kenya, Kuwait, Latvia, Malaysia, Netherlands, Oman, Pak
Initiated
Voluntary: Firm initiated
Recall number
Z-0597-2025

Ongoing Class II Medical devices

Recall started
21 October 2024
Reason
Potential for falsely depressed auto-diluted results for samples above the measuring interval of 18.00 mg/L, up to 30.00 mg/L, when using the Atellica CH ¿2-Microglobulin (B2M) reagent.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czech Republic, Denmark, Ecuador, Egypt, Finland, France, Germany, Greece, Hungary, India, Iran, Israel, Italy, Ivory Coast, Japan, Jordan, Kuwait,
Initiated
Voluntary: Firm initiated
Recall number
Z-0599-2025

Ongoing Class II Medical devices

Recall started
21 October 2024
Reason
A manufacturing defect causes Atellica CH Reaction Ring Cuvette Segments with lot numbers N15 on the packaging or 15 on the underside of the cuvette segment have a potential for imprecision and erroneously depressed or elevated QC and patient results for seven (7) analytes: Ammonia, Acetaminophen, Alanine Aminotransferase (ALT), Hemoglobin A1c, Creatinine Kinase (CK), Cystatin C, and Salicylate.
Distribution
US Nationwide and Worldwide distribution: Foreign: Algeria Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile China Colombia Congo, Republic C¿te dIvoire Croatia Cyprus Czech Republic Denmark Ecuador Egypt Estonia Finland France Germany Greece Ho
Initiated
Voluntary: Firm initiated
Recall number
Z-0496-2025

Ongoing Class II Medical devices

Recall started
30 September 2024
Reason
The IMMULITE 2000 PSA assay for use on the IMMULITE 2000 and IMMULITE 2000 XPi analyzers did not meet the High-dose Hook Effect claim as stated in the Instructions for Use (IFU).
Distribution
Worldwide - US Nationwide distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0464-2025

Ongoing Class II Medical devices

Recall started
24 September 2024
Reason
Siemens Healthcare Diagnostics Inc. has confirmed that a negative sodium bias may exist in one lot of epoc BGEM BUN Test Cards approximately 2 months prior to expiration. The observed maximum negative bias from internal testing is -10 mmol/L. No positive bias has been observed. Quality Control (QC) fluid may or may not detect the issue depending on the bias magnitude and the frequency of QC testing. One customer complaint has been associated with this issue. No adverse events have been reported. All affected lots have recently expired before the issuance of the recall.
Distribution
US Nationwide. Canada.
Initiated
Voluntary: Firm initiated
Recall number
Z-0286-2025

Ongoing Class II Medical devices

Recall started
21 August 2024
Reason
Positive bias in patient results at and below the cut-off of 60 U/mL with the lots listed in the table below when compared to alternate lots on the Atellica IM analyzer.
Distribution
Worldwide distribution - US Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-3305-2024, Z-3304-2024

Ongoing Class II Medical devices

Recall started
15 August 2024
Reason
Atellica CH Microalbumin_2 (¿ALB_2) and the ADVIA Chemistry Microalbumin_2 (¿ALB_2) are not meeting the High-Dose Hook Effect claim/Prozone Effect claim as stated in the Instructions for Use (IFU) on the Atellica CH, Atellica CI Analyzers, ADVIA 1800 Chemistry Systems, ADVIA 2400 Chemistry Systems, and ADVIA Chemistry XPT Systems, may result in erroneously depressed microalbumin patient results.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bahrain, Bangladesh, Belgium, Bosnia Herzeg, Brazil, Canada, Chile, Colombia, Croatia, Cura¿ao, St. Eus, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Ho
Initiated
Voluntary: Firm initiated
Recall numbers
Z-3169-2024, Z-3170-2024

Ongoing Class II Medical devices

Recall started
30 July 2024
Reason
During manufacturing, the last three tests from the 160 test flex of lot 23206BA (wells 8 or 10) were processed on the Dimension Vista platform. There was an issue with the filling line which led to some wells to underfill in lot 23206BA. Calibrator, quality control (QC) and patient results could have been impacted.
Distribution
Domestic: Nationwide Distribution. International: Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Italy, Qatar, Slovenia, Spain, Switzerland.
Initiated
Voluntary: Firm initiated
Recall number
Z-3065-2024

Ongoing Class II Medical devices

Recall started
29 July 2024
Reason
The potential for biased quality control (QC) and patient results when using Atellica CH UCFP lot 130414 and ADVIA Chemistry UCFP lot 140 reagents.
Distribution
Worldwide - US Nationwide distribution in the states of CA, FL, GA, IA, IL, KY, LA, MS, NJ, NY, NV, PA, TX, VA, PR and the countries of Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Canada, Chile, China, Columbia, Croatia, Cura¿ao, St Eus, Czech Republic, Egypt, Estonia, Finland, France,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-3063-2024, Z-3064-2024

Ongoing Class II Medical devices

Recall started
26 July 2024
Reason
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
Distribution
Worldwide - US Nationwide distribution
Initiated
Voluntary: Firm initiated
Recall numbers
Z-3100-2024, Z-3103-2024, Z-3102-2024, Z-3104-2024, Z-3101-2024

Ongoing Class II Medical devices

Recall started
17 May 2024
Reason
Siemens Healthineers has identified an issue with the RAPIDPoint500e system software version 5.3. This issue affects how the sample source is identified at the LIS when using the capillary mode. With this software version, samples run in the capillary mode are incorrectly labeled as arterial when displayed on the LIS, leading to the potential for results to be flagged according to an established arterial range. Capillary sample results are correctly identified as capillary on both the RAPIDPoint 500e system display and the instrument printouts. The issue only affects the new software version 5.3 and only capillary sample mode is impacted. The inability to distinguish specimen sources for blood gas may lead to incorrect diagnoses and management decisions.
Distribution
Worldwide - US Nationwide distribution in the states of FL, GA, LA, MI, NC and the countries of Chile, Costa Rica, France, Germany, Japan, Lebanon, Mexico, Netherlands, New Zealand, Poland, Spain, Turkey, United Kingdom.
Initiated
Voluntary: Firm initiated
Recall number
Z-2214-2024

Ongoing Class II Medical devices

Recall started
23 April 2024
Reason
The potential for falsely elevated patient sample results when using impacted lots (782, 783, 785, 786, 787, 788, 789, 790, 791, 792 and 793), of IMMULITE 2000 Anti-TG Ab.
Distribution
Worldwide - US Nationwide distribution including in the states of AL, CA, DC, FL, HI, ID, IN, KS, KY MA, MI, MN, MO, NC, NJ, NY, OH, OR, PA, PR, TX, WA WI and the countries of Argentina, Australia, Austria, Bangladesh, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Croatia
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1886-2024, Z-1887-2024

Ongoing Class II Medical devices

Recall started
13 March 2024
Reason
Potential for falsely elevated Chol_2, LDLC, and Trig_2 results on the Atellica CH and Atellica CI analyzers when the previous result in the cuvette was Iron3. Results in a positive bias ranging from 2-16% -impacts calibrator, quality control (QC), and patient results.
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Curacao, St¿Eus, Czech Republic, Denmark, Estonia, Finland, France, Germany, ¿ Greece, Hungary, India, Ireland, Israel, Italy,
Initiated
Voluntary: Firm initiated
Recall number
Z-1549-2024

Ongoing Class II Medical devices

Recall started
7 February 2024
Reason
The reason for the recall is that the Siemens DCA HbA1c Reagent Kit was confirmed to display a positive bias without alerting the user. The potential impact of the defect is that erroneous test results could be reported and potentially lead to incorrect patient management of glucose control. A positive bias may be observed with eleven HbA1c affected lots. Positive bias was observed when the performance of these five HbA1c lots was compared to NGSP pooled patient target-value assigned samples and the maximum bias observed was 19%.
Distribution
Worldwide distribution - US Nationwide and the country of Taiwan.
Initiated
Voluntary: Firm initiated
Recall number
Z-1304-2024

Ongoing Class II Medical devices

Recall started
24 January 2024
Reason
Siemens Healthcare Diagnostics has confirmed an average negative bias of -35% compared to the 3rd World Health Organization (WHO) International Standard (NIBSC code: 11/170) that is proportional across the assay measuring interval. The reference interval as claimed in the Instructions for Use (IFU) is not achieved with affected lots.
Distribution
Worldwide - US Nationwide distribution in the states of AL, CA, IA, IL, MI, MN, NC, NE, NV, NY, OH and TX; The countries of Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Colombia, Croatia, Czech Republic, Denmark, Ecuador, Egypt, France, Germany, Greece, India, Italy, Japan, Latvia, Mala
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1280-2024, Z-1281-2024

Ongoing Class II Medical devices

Recall started
15 December 2023
Reason
Potential for a negative bias with quality control (QC) and patient sample results when using the Atellica CH Immunoglobulin M_2 (IgM_2) reagent.
Distribution
Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, CO, CT, DC, FL, GA, IA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NM, NV, NY, OH, OR, PA, SC, TN, TX, UT, VA, WA, WI, and PR; The countries of Argentina, Australia, Austria, Bahrain, Belgium,
Initiated
Voluntary: Firm initiated
Recall number
Z-1003-2024

Ongoing Class II Medical devices

Recall started
26 October 2023
Reason
RAPIDPoint 500 Systems Measurement Cartridges (with lactate) has the potential to affect the Sodium (Na+) sensor to produce a negative bias that could result in serious injury due to a delayed diagnosis of hypernatremia or unnecessary intervention for hyponatremia and result in iatrogenic hypernatremia especially if the true sodium result is near the thresholds of severe alterations, as well as cause a Question Result -----? error flag for multiple electrolytes on patient samples and quality control that may cause a delay of diagnosis or treatment.
Distribution
Nationwide with Worldwide Distribution to: Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahrain Bangladesh Belarus Belgium Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Darussalam Bulgaria Burkina Faso Cambodia Canada Chile China Colombia Congo, Republic Costa Rica
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0607-2024, Z-0608-2024, Z-0609-2024, Z-0606-2024

Ongoing Class II Medical devices

Recall started
19 October 2023
Reason
Siemens Healthcare Diagnostics Inc. has confirmed a potential issue that could occur under certain conditions, a software problem is causing erroneous results to be printed. When the results are run on the epoc NXS Host and Delete Blood Tests feature is enabled, the results that are generated at the time of testing are correct; however, when this issue occurs, results that are printed, saved and/or transferred to a data manager, may include unselected analytes that are from a previous patient or QC test. The worst possible outcome may result in a failure to diagnose hyperkalemia, due to an erroneous depressed potassium level or inappropriate treatment to hyperglycemia due to erroneous glucose reading.
Distribution
US Nationwide. Global Distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0601-2024

Ongoing Class II Medical devices

Recall started
26 September 2023
Reason
There are potential drug interferences from Perhexiline Maleate or Atomoxetine Hydrochloride that may cause falsely elevated sodium results reported on the RAPIDPoint 500 and RAPIDPoint 500e Blood Gas Systems. The erroneous sodium levels with positive bias may lead to unrecognized hyponatremia and/or the inappropriate treatment of hypernatremia may lead to iatrogenic hyponatremia, resulted in a delay in patient diagnosis and optimal patient management.
Distribution
Domestic: Nationwide Distribution. Foreign: Albania, Algeria, Angola, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Cambodia, Canada, Chile, China, Colombia, Con
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0423-2024, Z-0422-2024

Ongoing Class II Medical devices

Recall started
8 August 2023
Reason
There is a potential for a positive bias on Quality Control (QC) and patient sample results when using some IRON_2 reagent wedge pairs. When the issue occurs, the observed bias will vary wedge to wedge.
Distribution
US Nationwide. Global Distribution
Initiated
Voluntary: Firm initiated
Recall number
Z-2666-2023

Ongoing Class II Medical devices

Recall started
25 July 2023
Reason
There is a potential for ADVIA Chemistry Urinary/Cerebrospinal Fluid Protein reagent carryover impacting Enzymatic Creatinine_2 (ECRE_2). Falsely depressed ECRE_2 results may be observed when the assay is processed after the UCFP test on ADVIA Chemistry systems.
Distribution
Worldwide - US Nationwide distribution in the states of CA, CO, CT, FL, GA, IA, MD, MI, NJ, NM, NY, OH, PA, SD, TX, UT, and VA. Global distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-2451-2023

Ongoing Class II Medical devices

Recall started
10 July 2023
Reason
Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica¿CH Total Bilirubin_2 (TBil_2), Atellica¿ CH LDL Cholesterol (LDLC), Atellica¿ CH Gamma-Glutamyl Transferase (GGT) and Atellica¿ CH HDL Cholesterol (HDLC)
Distribution
US Nationwide - Worldwide Distribution Foreign: Taiwan Uruguay Vietnam
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2473-2023, Z-2474-2023, Z-2471-2023, Z-2472-2023

Ongoing Class II Medical devices

Recall started
1 June 2023
Reason
There is potential for discrepant high glucose results in samples with glucose results on the lower end of the reportable range.
Distribution
US distribution to AL, AR, AZ, CA, CO, DC, DE, FL, IA, ID, IL, KS, KY, LA, MI, MN, MO, NC, ND, NH, NY, OH, OK, SC, SD, and TX OUS distribution to Canada, China, Colombia, Finland, India, Mexico, Norway, Sweden, United Arab Emirates, and Vietnam
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2477-2023, Z-2478-2023, Z-2476-2023

Ongoing Class II Medical devices

Recall started
16 May 2023
Reason
A firmware error may lead to an incorrect association of test result(s) to a sample ID and therefore to an incorrect patient result. The mis-association of test results, or a delay in testing, may occur when all the conditions listed below occur within a few milliseconds timeframe of each other: - The SRM module is releasing a sample tube (Tube A) just placed into the carrier - Another sample tube (Tube B) is erroneously not diverted into the SRM module buffer - There is divert gate malfunction and a narrow timing window Only in this specific scenario, Tube A may be released by the module as Tube B due to a miscommunication between the module firmware and the Automation software without a unique error message being generated. The Automation System loses the traceability of Tube A. It manages both Tube A (incorrectly identified as Tube B) and the real Tube B according to the pending test orders (not yet performed) on Tube B.
Distribution
Worldwide distribution - US Nationwide distribution in the states of CA, CO, FL, IL, KY, LA, MA, MD, MI, MS, MT, NC, NH, NY, OH, PA, SC, TN, TX, VA, WA, & WV. The countries of Australia, Brazil, Canada, China, France, Germany, Greece, Italy, Portugal, Saudi Arabia, Spain, Sweden, & United Kingdom.
Initiated
Voluntary: Firm initiated
Recall number
Z-2091-2023

Ongoing Class II Medical devices

Recall started
5 April 2023
Reason
Reassignment of the Atellica CH Toxicology Calibrators (TOX CAL) and ADVIA Chemistry ToxAmmonia Calibrators for the Atellica CH Salicylate (Sal) Assay due to a positive bias
Distribution
US Nationwide and Worldwide Distribution Foreign: Argentina Australia Austria¿¿¿¿¿¿¿¿ Bahrain¿¿¿¿¿¿¿¿ Bangladesh Belgium¿¿¿¿¿¿¿¿ Bosnia¿Herzeg.¿ Brazil Canada Chile China Colombia Czech¿Republic¿ Egypt¿¿¿¿¿¿¿¿¿¿ Estonia¿¿¿¿¿¿¿¿ Finland¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Georgia¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1632-2023, Z-1631-2023

Ongoing Class II Medical devices

Recall started
16 March 2023
Reason
There is a negative bias with urine patient samples and urine cortisol Quality Control (QC) results intermittently out of range low.
Distribution
Worldwide distribution - US Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1504-2023, Z-1505-2023

Ongoing Class II Medical devices

Recall started
30 January 2023
Reason
Siemens Healthineers has received customer complaints and confirmed imprecision for Quality Control (QC) and patient samples with Dimension Tacrolimus (TAC) lots GA2286, GA3047 and GA3171. The health consequences of erroneous patient results are major, since in a worst case scenario, a patient s tacrolimus dosing could be altered, resulting in potential organ failure and rejection (due to too low or no tacrolimus being administered) or toxicity (due to too much tacrolimus being administered). Siemens internal investigation of the Dimension TAC assay showed the worst case imprecision with patient samples at the low end of the Analytical Measurement Range (AMR). A patient sample at 2.0 ng/mL (2.6 nmol/L) recovered as 0.0 ng/mL (0.0 nmol/L) (100% negative bias), another patient sample at 2.1 ng/mL (2.7 nmol/L) recovered at 4.3 ng/mL (5.6 nmol/L) (103% positive bias).
Distribution
Worldwide and Nationwide Distribution Foreign: Aregentina Brazil Chile Colombia Country India Japan New Zealand Nicaragua Saudi¿Arabia¿¿¿ South Africa South Korea Spain¿¿¿¿¿¿¿¿¿¿ Sri Lanka Taiwan
Initiated
Voluntary: Firm initiated
Recall number
Z-1258-2023

Ongoing Class II Medical devices

Recall started
27 January 2023
Reason
Reagent Carryover from LDL Cholesterol Direct (DLDL), Total Protein II (TP), Triglycerides (Trig), and Triglycerides_2 (Trig_2) Impacting Magnesium (Mg) Results
Distribution
Nationwide Foreign: Country Albania Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile China Colombia Croatia Cura¿ao Czech Republic Denmark Ecuador Egypt Finland France Germany Greece Guadeloupe Hong Kong Hungary India Ireland Israel Italy Japan
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1270-2023, Z-1268-2023, Z-1269-2023, Z-1271-2023

Ongoing Class II Medical devices

Recall started
9 January 2023
Reason
Negative bias occurred when whole blood calibration (Atellica IM Fol or ADVIA Centaur FolateBA/FolBA) used to test serum samples.
Distribution
Nationwide Foreign: Albania¿¿¿¿¿¿¿¿ Austria¿¿¿¿¿¿¿¿ Bahrain¿¿¿¿¿¿¿¿ Belgium¿¿¿¿¿¿¿¿ Bosnia¿Herzeg.¿ Bulgaria¿¿¿¿¿¿¿ Croatia¿¿¿¿¿¿¿¿ Cura¿ao,¿St¿Eus Cyprus¿¿¿¿¿¿¿¿¿ Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ Estonia¿¿¿¿¿¿¿¿ Finland¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Georgia¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿¿¿ Hungary¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1149-2023, Z-1151-2023, Z-1152-2023, Z-1150-2023, Z-1154-2023, Z-1153-2023

Ongoing Class II Medical devices

Recall started
22 December 2022
Reason
Anti-HBe2 (aHBe2) interference with the Hepatitis B e Antigen (HBeAg) Assay, leads to elevated or reactive Hepatitis B e Antigen (HBeAg) results on samples that are non-reactive when HBeAg testing follows aHBe2 testing, regardless of whether both tests are performed on the same sample
Distribution
US Nationwide distribution in the states of GA, UT.
Initiated
Voluntary: Firm initiated
Recall number
Z-1143-2023

Ongoing Class II Medical devices

Recall started
12 December 2022
Reason
pO2 High Recovery in Quality Control When Adjusted for Barometric Pressure
Distribution
Nationwide Foreign: Algeria Argentina Australia Austria Bahrain Belarus Belgium Bolivia Brazil Cambodia Canada Chile China Colombia Croatia Czech Republic Denmark Ecuador Egypt Estonia Finland France Fren.Polynesia Georgia Germany Greece Guadeloupe Hong Kong Hungary Iceland India Indonesia Iran Irel
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1214-2023, Z-1215-2023

Ongoing Class II Medical devices

Recall started
7 December 2022
Reason
Potential for Functional Sensitivity to not meet Instructions For Use (IFU) claims with the kit lots; control level one may result outside of published ranges; when control results are in range, users may observe increased imprecision with low level patient samples
Distribution
Nationwide Foreign: Argentina¿¿¿¿¿¿ Australia¿¿¿¿¿¿ Austria¿¿¿¿¿¿¿¿ Bahrain¿¿¿¿¿¿¿¿ Bangladesh¿¿¿¿¿ Belgium¿¿¿¿¿¿¿¿ Bolivia¿¿¿¿¿¿¿¿ Bosnia¿Herzeg.¿ Brazil¿¿¿¿¿¿¿¿¿ Bulgaria¿¿¿¿¿¿¿ Canada¿¿¿¿¿¿¿¿¿ Chile¿¿¿¿¿¿¿¿¿¿ Colombia¿¿¿¿¿¿¿ Costa¿Rica¿¿¿¿¿ Croatia¿¿¿¿¿¿¿¿ Cyprus¿¿¿¿¿¿¿¿¿ Czech¿Republic¿ Dominica
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0949-2023, Z-0950-2023

Ongoing Class II Medical devices

Recall started
4 November 2022
Reason
Potential for falsely elevated specific IgE mold allergen reactivity with quality control material and patient samples, may result in false reactive result
Distribution
Worldwide distribution. US Nationwide, Argentina¿¿¿¿¿¿ Australia¿¿¿¿¿¿ Austria¿¿¿¿¿¿¿¿ Azerbaijan¿¿¿¿¿ Belgium¿¿¿¿¿¿¿¿ Brazil¿¿¿¿¿¿¿¿¿ Chile¿¿¿¿¿¿¿¿¿¿ Colombia¿¿¿¿¿¿¿ Costa¿Rica¿¿¿¿¿ Croatia¿¿¿¿¿¿¿¿ Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ Ecuador¿¿¿¿¿¿¿¿ Egypt¿¿¿¿¿¿¿¿¿¿ Estonia¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Germ
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0718-2023, Z-0716-2023, Z-0717-2023

Ongoing Class II Medical devices

Recall started
25 October 2022
Reason
Confirmed an average positive bias of 40% for testosterone concentrations of approximately 660 ng/dL (22.9 nmol/L) and above with the IMMULITE/IMMULITE 1000 Total Testosterone Assay when compared to the IMMULITE 2000/IMMULITE 2000 XPi Total Testosterone Assay. Two (2) lots of Total Testosterone assays for the IMMULITE/IMMULITE 1000, kit lots #515 and #516 were actively distributed to customers when the issue was discovered by Siemens, and they are subject to the correction or removal in this recall (867 total quantity of reagents distributed for each lot). The violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. In both males and female, testosterone results are not used in isolation but are interpreted in conjunction with clinical history and symptomology as well as with other laboratory testing (e.g. gonadotropins and other sex steroids). A delay in the diagnosis may be experienced and medical intervention, such as repeat testing may be required.
Distribution
Worldwide Distribution: US (nationwide) to states of: AL, CA, FL, GA, IN, KY, NC, NE, OR, SD, TX, UT; and OUS (Foreign) to countries of: Canada, Mexico, Austria, Argentina, Austria, Bangladesh, Colombia, Brazil, Bulgaria, Costa¿Rica, Cyprus, Estonia, Germany, Greece, India, U.A.E.,
Initiated
Voluntary: Firm initiated
Recall number
Z-0355-2023

Ongoing Class II Medical devices

Recall started
19 September 2022
Reason
Potential for falsely elevated LITH_2 and Li results on the Atellica CH 930 Analyzer. In the worst case, there is a potential for erroneously elevated lithium patient results, which may lead to inappropriate dosage adjustment, potentially affecting treatment efficacy.
Distribution
Worldwide distribution - US Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0105-2023, Z-0104-2023

Ongoing Class II Medical devices

Recall started
30 August 2022
Reason
N Antiserum to Human IgG are not meeting the current High-Dose Hook Effect expectation of up to 648 mg/L for IgGU (urine) and up to 2290 mg/L for IgGC (CSF).
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0093-2023, Z-0094-2023

Ongoing Class II Medical devices

Recall started
24 August 2022
Reason
Dimension Vista¿ High Density Lipoprotein Cholesterol (HDLC) Potential for Erroneous Result. If an HDLC QC or patient result is obtained without an Abnormal Reaction [E145]: flag, a falsely depressed or elevated result ranging from -90% to 133% may be observed.
Distribution
Nationwide Foreign: Canada
Initiated
Voluntary: Firm initiated
Recall number
Z-0089-2023

Ongoing Class II Medical devices

Recall started
17 August 2022
Reason
Dimension Magnesium (MG) Flex reagent cartridge lots may exhibit imprecision for Quality Control (QC) and produce Abnormal Reaction flags. The issue is not always detected by QC and erroneous results may be produced in the absence of an Abnormal Reaction flag. Based on customer data, imprecision leading to erroneous, unflagged patient results with a bias of -15 to -59% may occur
Distribution
Nationwided Foreign: Afghanistan¿¿¿¿ Albania¿¿¿¿¿¿¿¿ Austria¿¿¿¿¿¿¿¿ Bahrain¿¿¿¿¿¿¿¿ Bosnia¿Herzeg.¿ Bulgaria¿¿¿¿¿¿¿ Canada Croatia¿¿¿¿¿¿¿¿ Czech¿Republic¿ Egypt¿¿¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Georgia¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿¿¿ Hungary¿¿¿¿¿¿¿¿ Israel¿¿¿¿¿¿¿¿¿ Italy¿¿¿¿¿¿¿¿¿¿ Jordan¿¿¿
Initiated
Voluntary: Firm initiated
Recall number
Z-1816-2022

Ongoing Class II Medical devices

Recall started
11 August 2022
Reason
An average negative bias of -23% with IMMULITE 2000/IMMULITE 2000 XPi Thyroid Stimulating Immunoglobulins (TSI) when compared to other in-date kit lots, there is a potential for erroneously depressed patient results. This may lead to a delayed follow up of patients with clinical autoimmune thyroid
Distribution
Worldwide Distribution: US (nationwide) to states of: FL IN MA MI NH NJ NY OH TX UT and OUS (Foreign) countries of: Aus
Initiated
Voluntary: Firm initiated
Recall number
Z-1820-2022

Ongoing Class II Medical devices

Recall started
18 July 2022
Reason
Negative bias with patient samples. The mean patient sample bias range from -26% to -33%,potential risk of delay in appropriate treatment and management decisions.
Distribution
Worldwide distribution - US Nationwide and the countries of Canada, Austria, France, ¿¿ Germany, Italy, Switzerland.
Initiated
Voluntary: Firm initiated
Recall number
Z-1648-2022

Ongoing Class II Medical devices

Recall started
28 June 2022
Reason
Falsely Elevated Atellica CH Microalbumin_2 (¿ALB_2) Results due to Reagent Carryover from the Iron_2 Assay. This defect occurs only when a microalbumin test is run immediately after an iron test.
Distribution
Worldwide distribution - US Nationwide and the countries of AR, AU, AT, BS, BH, BD, BE, BR, BG, BF, CA, CL, CO, HR, CW, CZ, DK, EC, EG, EE, FI, FR, DE, GR, GP, HK, HU, IN, IR, IQ, IE, IL, IT, JP, JO, KE, KW, LV, LY, LT, MY, MX, MA, NL, NZ, NO, OM, CN, PK, PY, PE, PH, PL, PT, QA, KR, RO, RU, SA, R
Initiated
Voluntary: Firm initiated
Recall number
Z-1498-2022

Ongoing Class II Medical devices

Recall started
1 June 2022
Reason
Discrepant (low bias) pO2 results, could be an incorrect diagnosis of hypoxemia and initiation of unnecessary or inappropriate respiratory support.
Distribution
AL CA CO FL IA ID KS NM OK TX
Initiated
Voluntary: Firm initiated
Recall number
Z-1372-2022

Terminated Class II Medical devices

Recall started
18 May 2022
Terminated
13 February 2025
Reason
Positive bias with Lithium Heparin plasma samples from individuals that are expected to be below the 99th percentile of 0.07 ng/mL [0.07 ¿g/L], may lead to inappropriate intervention for myocardial infarction
Distribution
Worldwide distribution - US Nationwide distribution in the states of AL, AR, CA, IL MN, MS, NC, ND, NH, OK, SD, TN, TX, WA and the countries of Argentina, Brazil, Canada, France, Germany, India, Mexico, Poland, Portugal, Slovakia, Spain.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1340-2022, Z-1341-2022

Ongoing Class II Medical devices

Recall started
13 April 2022
Reason
Lots incompatible with Test Definition (TDef) Version 1.4, potentially lead to the generation of erroneous total T3 results
Distribution
Worldwide distribution - US Nationwide and the countries of Albania, Argentina, Austria, Bahamas, Bangladesh, Belgium, Brazil, Chile, China, Columbia, Croatia, Czech¿Republic, Denmark, Ecuador, Egypt, France, Germany, Greece, India, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Netherlands,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1252-2022, Z-1253-2022

Ongoing Class II Medical devices

Recall started
3 March 2022
Reason
Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Distribution
Worldwide distribution - US Nationwide and the countries of Austria, Belgium, Brazil, Bulgaria, Burkina, Faso Country AG, Cyprus, Denmark, Egypt, Estonia, Finland, France, French Polynesia, Georgia, Greece, Guadeloupe, India, Ireland, Israel, Italy, Kazakhstan, Latvia, Lithuania, Macedonia, Malta, M
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1024-2022, Z-1025-2022, Z-1022-2022, Z-1021-2022, Z-1023-2022, Z-1020-2022

Ongoing Class II Medical devices

Recall started
22 February 2022
Reason
Potential for falsely elevated hCG results due to sample carryover in serum and urine patient samples, as well as quality control samples and adjustors.
Distribution
Worldwide distribution - US Nationwide distribution in the states of AZ, CA, CO, FL, GA, HI, ID, IN, MN, NC, NH, NJ, NM, NV, NY, OH, OR, PA, SC, TX, VA, WI, WY and OUS: 81 countries.
Initiated
Voluntary: Firm initiated
Recall number
Z-1015-2022

Ongoing Class II Medical devices

Recall started
9 February 2022
Reason
Siemens Healthcare Diagnostics Inc. has confirmed the potential for reagent carryover impacting quality control (QC), patient samples, and calibrator results.
Distribution
Global Distribution. US Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0930-2022, Z-0931-2022, Z-0929-2022, Z-0928-2022

Ongoing Class II Medical devices

Recall started
28 January 2022
Reason
Dimension Vista Magnesium Flex reagent cartridge lots exhibiting imprecision and intermittent Abnormal Assay flags. When this issue occurs, there is a potential for QC failures or erroneous patient results which may lead to repeat and follow-up testing.
Distribution
Worldwide distribution: US (nationwide) 47 States including: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY) and OUS countries of: Australia, Canada and Nether
Initiated
Voluntary: Firm initiated
Recall number
Z-0830-2022

Terminated Class II Medical devices

Recall started
1 December 2021
Terminated
7 July 2023
Reason
¿2 Microglobulin (B2M) Reagent Lot 211446 Bias with Quality Control and Patient Sample Results. Positive bias on patient samples of up to +20.9% at a B2M concentration of approximately 1.5 mg/L and a negative bias on patient samples of up to -10.5% at a B2M concentration of approximately 15 mg/L
Distribution
Worldwide distribution - US Nationwide distribution in the states of CA, CO, MA, MD, MS, NC, NE, NH, OH, VA, WI and the countries of Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Czech Republic, Denmark, Ecuador, France, Germany, Greece, India, Iran, Israel, Italy, Japan, Mexico, Morocc
Initiated
Voluntary: Firm initiated
Recall number
Z-0440-2022

Ongoing Class II Medical devices

Recall started
18 November 2021
Reason
(1)Software (SW) versions V1.25.1 and lower may result in TDef (Test Definition) Parameters for Open Channel Assays reverting to Default Value would shift test results by the magnitude of the implemented Assay Correlation factor; (2) On Board Stability (OBS) Not Updating with Manual Change for Open Channel Assays may continue to use the reagent past its expiration date leading to potential erroneous patient sample results
Distribution
Nationwide Foreign: AU DE AE TR BG CL IN CZ BR ES KE CN PL SA BE IQ IT CW SE AR CO GR SK EE KR JP UY DK FR GB VN CA BD MX TH DZ PT RU ZA PK HU NL VA NO AT IR LV EG PH SG MY IL FI HR MA KW CH TW BH AL BF UG NZ OM HK QA PE EC IE GP LY LT
Initiated
Voluntary: Firm initiated
Recall number
Z-0449-2022

Terminated Class II Medical devices

Recall started
15 October 2021
Terminated
13 May 2024
Reason
Incorrect Default Hemolysis, Icterus or Lipemia (HIL) Index for Five Dimension Vista Assays
Distribution
Worldwide distribution - US Nationwide distribution and the countries of DE, ES, FR, IT, CA, NL, JP, PT, AU, CZ, AT, DK, SI, BE, SK, QA, SA, KR, CH.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0331-2022, Z-0330-2022

Ongoing Class II Medical devices

Recall started
6 October 2021
Reason
The Aptio Automation Firmware for the ADVIA Centaur XP/XPT Interface Module may lead, in some cases, to an incorrect association of test results to sample ID. Incorrect association of test results could impact clinical interpretations and clinical decisions.
Distribution
Worldwide distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0193-2022

Ongoing Class II Medical devices

Recall started
28 September 2021
Reason
Ancillary reagent packs used on Atellica IM 1300 and Atellica IM 1600 analyzers may overflow when pierced while on an analyzer located at an altitude of greater than 350m (1148ft) above sea level. As a result, customers at these altitudes may observe an increased number of Reagent Volume Check Errors.
Distribution
Domestic distribution to AZ CA CO GA ID KS MO MT NC NE NM NV OH OK OR PA TN TX UT VA WA WI WY. Foreign distribution worldwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0125-2022, Z-0124-2022

Terminated Class II Medical devices

Recall started
22 September 2021
Terminated
2 August 2022
Reason
Data provided in the Emergency Use Authorization (EUA) submission was insufficient to determine that the assays were adequately validated for the intended use.
Distribution
US Nationwide distribution in the states of AK, CA, CO, DC, GA, IL, ME, NC, NV, NY, OR, PA, PR, VA and VI.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0196-2022, Z-0195-2022

Ongoing Class II Medical devices

Recall started
20 September 2021
Reason
The firm has confirmed the potential for ADVIA Chemistry Urinary/Cerebrospinal Fluid Protein reagent carryover impacting Enzymatic Hemoglobin A1c (A1c_E and A1c_EM) results. Falsely depressed Enzymatic Hemoglobin A1c results may affect consideration of intervention.
Distribution
Worldwide distribution - US Nationwide distribution.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0181-2022, Z-0180-2022

Ongoing Class II Medical devices

Recall started
6 July 2021
Reason
Product does not meet the Instructions for Use (IFU) claimed Pack Calibration Interval of 10 days. IFU calibration updated interval from 10 days to 3 days for all current and future kit lot numbers
Distribution
Worldwide distribution. US Nationwide, Australia, Bahamas, India, Mexico, Saudi Arabia, and Viet Nam
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2425-2021, Z-2426-2021, Z-2424-2021

Terminated Class II Medical devices

Recall started
18 May 2021
Terminated
30 August 2024
Reason
ADVIA Chemistry System and Software Versions (V1.4 SMN 11314625 and V1.4 China SMN 11316885) may not be aligned with customer expectations for the current default mixer failure detection setting of 2; an erroneously elevated or depressed patient result to be reported without alert on the test result
Distribution
Worldwide distribution - US Nationwide distribution in the states of CA, CO, CT, FL, MA, MD, MI, MN, NY, OH, PA, TX and the countries of Australia, Bahrain, Brazil, Canada, Chile, Croatia, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Italy, Malaysi
Initiated
Voluntary: Firm initiated
Recall number
Z-2014-2021

Ongoing Class II Medical devices

Recall started
13 May 2021
Reason
Valves used on the Atellica CH 930, Atellica IM 1300 and Atellica IM 1600 analyzers may develop a malfunction due to a manufacturing defect and may result in the valve wearing and leaking over time. The leaking is a risk in valves subject to high pressure or high wear and may impact the result accuracy of any assay.
Distribution
Nationwide Foreign: Country Name Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile Colombia Croatia Cura¿ao Cyprus Czech Republic Denmark Ecuador Egypt Estonia Finland France Germany Greece Hungary India Indonesia
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2027-2021, Z-2028-2021, Z-2026-2021

Ongoing Class II Medical devices

Recall started
4 May 2021
Reason
Photometer Lamp May Reach Saturation Without Flagging Results, may generate erroneously elevated or depressed patient results
Distribution
Worldwide distribution - US Nationwide and the countries of Albania, Algeria, Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Burkina Faso, Canada, Chile, Colombia, Croatia Cura¿ao, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Ho
Initiated
Voluntary: Firm initiated
Recall number
Z-1870-2021

Ongoing Class II Medical devices

Recall started
21 April 2021
Reason
Potential for the ADVIA Centaur Syphilis assay to carryover into other commercial assays. This carryover effect only occurs when the impacted assays are used immediately following testing with the Syphilis assay on the ADVIA Centaur XP/XPT or ADVIA Centaur CP systems
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Austria, Belgium, Burkina Faso, Croatia, Czech Republic, Egypt, Finland, France, Fren.Polynesia, Georgia, Germany, Germany, Greece, Guadeloupe, Italy, Kazakhstan, Latvia, Netherlands, Norway, Poland, Portugal, Qatar, Russian Fe
Initiated
Voluntary: Firm initiated
Recall number
Z-1674-2021

Ongoing Class II Medical devices

Recall started
5 March 2021
Reason
Potential Sample Identification (SID) Mismatch with14-Character Barcodes
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Albania, Algeria, Angola, Argentina, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Benin, Bosnia Herzeg., Botswana, Brazil, Bulgaria, Burkina, Faso, Cambodia, Canada, Chile, Colombia, Croatia, Cura¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1405-2021, Z-1394-2021, Z-1390-2021, Z-1396-2021, Z-1402-2021, Z-1386-2021, Z-1398-2021, Z-1395-2021, Z-1393-2021, Z-1403-2021, Z-1399-2021, Z-1401-2021 and 8 more

Terminated Class II Medical devices

Recall started
2 March 2021
Terminated
10 June 2022
Reason
Siemens Healthcare Diagnostics Products GmbH has confirmed that the BCS XP System may be affected by a potential Emicizumab carryover on patient samples.
Distribution
Worldwide distribution - US Nationwide distribution including in the states of AR, AZ, CA, CO, CT, FL, GA, IA, IL, IN, KY, LA, MA, MD, MI, MN, MO, MT, NC, NE, NJ, NY, OH, OK, PA, TN, TX, UT, VA, WA, WI, WV and the countries of Argentina, Austria, Belarus, Belgium, Bosnia Herzegovina, Brazil, Canada,
Initiated
Voluntary: Firm initiated
Recall number
Z-1435-2021

Terminated Class II Medical devices

Recall started
8 February 2021
Terminated
7 February 2025
Reason
Potential false positive HSV results. Siemens Healthcare Diagnostics, Inc. initiated a correction for ADVIA Centaur4P Herpes-2 lgG (HSV2) Onboard Stability and Calibration Frequency (Interval) Failures on the ADVIA Centaur XP System and ADVIA Centaur XPT System.
Distribution
Domestic: AL, CA, FL, IL, MD, NJ, NY, TN, TX. Foreign: Nepal, Chile, Georgia, Spain.
Initiated
Voluntary: Firm initiated
Recall number
Z-1274-2021

Ongoing Class II Medical devices

Recall started
3 February 2021
Reason
Siemens Healthcare Diagnostics Inc. has confirmed the potential for erroneous results due to discolored reagent observed in some wells 5 and 6 of Dimension Vista High Density Lipoprotein Cholesterol (HDLC) Flex reagent cartridges lot 20062BA.
Distribution
Worldwide distribution - US Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NM, NV, NY, OH, OR, PA, PR, SC, TN, TX, UT, VA, WA, WI, WV, WY, and the countries of Austria, Belgium
Initiated
Voluntary: Firm initiated
Recall number
Z-1188-2021

Terminated Class II Medical devices

Recall started
2 December 2020
Terminated
6 June 2024
Reason
Multiple issues in Software v1.23.2 and lower-may lead to the reporting of discrepant patient results
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Algeria, Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Cura¿ao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0862-2021, Z-0861-2021, Z-0863-2021

Ongoing Class II Medical devices

Recall started
23 November 2020
Reason
Gamma-Glutamyl Transferase (GGT) Reagent Low End Repeatability-Imprecision. Reagent may demonstrate a coefficient of variation (%CV) outside of the performance data for repeatability (within-run) listed in the Instructions For Use (IFU) on some analyzers.
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Australia, Austria, Bahamas, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, India, Iran, Ireland, Is
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0722-2021, Z-0721-2021

Terminated Class II Medical devices

Recall started
26 October 2020
Terminated
19 April 2024
Reason
Test Definition scanning may reset custom settings to defaults causing falsely low or high results. When a 2D Master Curve and TDef barcode for a new kit lot of reagent is scanned and the TDef version is a newer version than the version that is currently on the system, some of the customer defined settings for that assay may reset to default values
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Algeria, Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Cura¿ao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, German
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0473-2021, Z-0474-2021

Ongoing Class II Medical devices

Recall started
22 September 2020
Reason
Fructosamine QC and patient samples may exhibit a 60 umol/L positive bias across the measuring range compared to predicate assay reference leading to a potential adjustment of hyperglycemic therapy. Positively biased fructosamine results may prompt changes in glucose management that may affect glycemia. In extreme situations, more aggressive management of glycemia may occur and contribute to hypoglycemia.
Distribution
CA, DE, MD, NC, NJ, NY, PA Foreign: Argentina¿¿¿¿¿¿ Australia¿¿¿¿¿¿ Brazil¿¿¿¿ Canada¿¿¿¿¿ Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Italy¿¿¿¿¿¿¿¿¿¿ Netherlands¿¿¿¿ P.R.¿China¿¿¿¿¿ Paraguay¿¿¿¿¿¿¿ Slovakia¿¿¿¿¿¿¿ Turkey¿¿¿¿¿¿¿¿¿ United¿Kingdom¿ Vietnam¿¿¿¿¿¿¿¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0101-2021, Z-0102-2021

Terminated Class II Medical devices

Recall started
28 August 2020
Terminated
9 September 2021
Reason
Sporadically inconsistent discrepant (low bias) glucose results on card lot 01-20095-10. Potential exists for a delay in diagnosis of hyperglycemia or unnecessary treatment for hypoglycemia.
Distribution
Nationwide Foreign: Canada
Initiated
Voluntary: Firm initiated
Recall number
Z-2970-2020

Terminated Class II Medical devices

Recall started
25 August 2020
Terminated
4 May 2023
Reason
Low outlier resultsgenerated with Alkaline Phosphatase (ALPI) Flex reagent cartridge.The maximum difference observed with a patient sample was approximately -27% at a concentration of 129 U/L (2.15 ukat/L). The low outlier results are generated from the last five (5) tests of the well
Distribution
Worldwide distribution - US Nationwide and the countries of Canada, Australia, Austria, Belgium, Bahamas, Czech Republic, Denmark, France, Germany, Italy, Japan, Korea, Netherlands, Norway, New Zealand, Portugal, Slovakia, Slovenia, Spain, Switzerland.
Initiated
Voluntary: Firm initiated
Recall number
Z-0134-2021

Terminated Class II Medical devices

Recall started
25 August 2020
Terminated
10 March 2023
Reason
Siemens confirmed that the Upper Limit of Normal (ULN) as claimed in the Instructions for Use (IFU) was no longer achieved. This can potentially result in false positive or false negative results.
Distribution
US Nationwide distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0115-2021

Terminated Class II Medical devices

Recall started
19 August 2020
Terminated
25 August 2023
Reason
Positive bias across the Analytical Measurement Range of the TNIH assay compared to an unaffected control lot. The average bias observed for patient samples using lots EB0255 and EA0178 of the Dimension EXL Troponin compared with a control lot was +25%. A maximum bias of +34% in patient samples around the 99th percentile observed
Distribution
US Nationwide distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0052-2021

Terminated Class II Medical devices

Recall started
24 July 2020
Terminated
7 June 2023
Reason
Dimension Vista High Sensitivity Troponin I (TNIH) may exhibit a negative bias with patient samples
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
Z-2927-2020

Terminated Class II Medical devices

Recall started
30 June 2020
Terminated
17 November 2020
Reason
If DCA Vantage Analyzer is configured to run Code 39 with check digit, the scanner is not confirming the integrity of read barcode data using the check digit. Also, if DCA Vantage Analyzer is configured to run Code 39 with check digit and an operator erroneously scans a Code 39 barcode without a check digit, the scanner incorrectly sends the code and the last character is removed.
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
Z-2747-2020

Terminated Class II Medical devices

Recall started
5 June 2020
Terminated
18 November 2021
Reason
Calibration errors have been observed with the Total and Direct Bilirubin assays when using Chemistry Calibrator lot 534177 for ADVIA Chemistry and lot 534179 for Atellica CH.
Distribution
US Nationwide Distribution
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2430-2020, Z-2431-2020

Terminated Class II Medical devices

Recall started
27 May 2020
Terminated
12 January 2021
Reason
The scanner is not confirming the integrity of read barcode data using the check-digit when reading Code 39 barcodes.
Distribution
Foreign distribution only.
Initiated
Voluntary: Firm initiated
Recall number
Z-2432-2020

Terminated Class II Medical devices

Recall started
15 May 2020
Terminated
18 May 2021
Reason
Unexpected interface driver behavior identified (QC) Results May Be Assigned to an Incorrect Control Lot Number, and lead to the reporting of erroneous patient results if the QC failed but appeared to be passing and the issue is not detected during QC review
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Argentina, Australia, Bahamas, Belgium, Brazil, Chile, Colombia, Czech Republic, Egypt, Germany, Greece, Hungary, India, Italy, Kuwait, Latvia, Lithuania, Malaysia, Mexico, Oman, Peru, Poland, Portugal, Qatar, Saudi Arabia,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2437-2020, Z-2438-2020

Terminated Class II Medical devices

Recall started
15 May 2020
Terminated
12 August 2022
Reason
Flexible tubing connected to the liquid waste bottle can crack during routine customer maintenance potentially causing liquid waste can leak onto the floor, creating a slip and fall hazard
Distribution
Worldwide distribution - US Nationwide distribution and the countries of AE, AO, AR, AT, AU, AZ, BA, BD, BE, BG, BH, BO, BR, BS, BY, CA, CH, CL, CN, CO, CY, CZ, DE, DK, DZ, EC, EE, EG, ES, FI, FR, GB, GE, GP, GR, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, JP, KR, KW, KZ, LB, LT, LU, LV, LY, ME,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2469-2020, Z-2470-2020

Ongoing Class II Medical devices

Recall started
7 May 2020
Reason
Insufficient sample may not be detected when using Tube Top Sample Cup (TTSC) or V-shaped Sample Cup sample containers with the Atellica IM1300 and IM1600 analyzers.
Distribution
Worldwide distribution including to the following states: Florida, New Jersey, New York, California, Arizona, Colorado, Pennsylvania, Virginia, Ohio, Texas, Alabama, Nebraska, Wisconsin, Montana, Kentucky, Washington DC, Massachusetts, North Carolina, Georgia, Louisiana, Kansas, South Carolina, Tenn
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2404-2020, Z-2405-2020

Terminated Class II Medical devices

Recall started
4 May 2020
Terminated
20 September 2021
Reason
The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples.
Distribution
Worldwide distribution - US Nationwide distribution including in the states of North Carolina, California, Indiana, Florida, Ohio, Arizona, Massachusetts, New Jersey, New Hampshire, Illinois, Minnesota, Arkansas, New York, Delaware, Nevada, Kentucky, Washington DC, Montana, Missouri, Colorado, Maryl
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2280-2020, Z-2283-2020, Z-2281-2020, Z-2284-2020, Z-2285-2020, Z-2282-2020

Terminated Class II Medical devices

Recall started
27 February 2020
Terminated
25 October 2021
Reason
Editing an assay Test Definition and switching to another assay s Test Definition screen without saving the changes using the save button on the screen, may corrupt the settings of the assay s test definition, and Auto-Rerun or Auto-Dilution results may generate a result of Zero (0) for quantitative assays or Negative for qualitative assays if a well of the reagent pack is not calibrated.
Distribution
US Nationwide. Global distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-1797-2020

Terminated Class II Medical devices

Recall started
14 February 2020
Terminated
22 February 2024
Reason
The assay may exhibit a positive bias in QC and patient results within the 10-day pack calibration interval.
Distribution
Domestic distribution nationwide. Foreign distribution to Australia, Austria, Bahamas, Belgium, Canada, Curacao, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, India, Israel, Italy, Japan, Kenya, Latvia, Mexico, Netherlands, Norway, Poland, Portugal, Slovakia, South Korea, Spain
Initiated
Voluntary: Firm initiated
Recall number
Z-1599-2020

Terminated Class II Medical devices

Recall started
13 February 2020
Terminated
23 April 2021
Reason
Bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy
Distribution
Nationwide Foreign: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, U
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1539-2020, Z-1540-2020, Z-1537-2020, Z-1538-2020, Z-1541-2020, Z-1536-2020

Terminated Class II Medical devices

Recall started
5 February 2020
Terminated
18 November 2021
Reason
Due to high discordant Estradiol results which.potentially affects all patient populations, A falsely elevated estradiol level could lead a clinician to misinterpret a patient as pre-menopausal when truly post- menopausal. This may lead to delayed initiation of a potentially beneficial drug and/or administration of an unnecessary drug in the treatment for hormone receptor positive advanced or metastatic breast cancer.
Distribution
Worldwide distribution - US Nationwide in the states of AL, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, IN, KY, LA, MA, MD, MI, NC, ND, NE, NJ, NV, NY, OH, OK, OR, PA, RI. SC, TN, TX, UT, VA, WA, WI, WY, and countries of AE, AF, AL, AO, AR, AT, AU, AZ, BD, BE, BO, BG, BH, BR, CA, CH, CO, CL, CN, CO,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1514-2020, Z-1513-2020

Ongoing Class II Medical devices

Recall started
12 January 2020
Reason
Some lots ending in "17", "18", "19", or higher may have cuvette defects allowing water from the water bath to contaminate the interior of the cuvette, which may falsely elevate or depress sample results.
Distribution
Domestic distribution nationwide. Worldwide foreign distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-1421-2020

Terminated Class II Medical devices

Recall started
6 January 2020
Terminated
11 July 2022
Reason
A software error is causing the analyzer to incorrectly eject affected Humidity Packs as expired.
Distribution
Domestic distribution nationwide. Foreign distribution worldwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1435-2020, Z-1436-2020

Terminated Class II Medical devices

Recall started
20 December 2019
Terminated
21 December 2020
Reason
Firm has received customer complaints regarding failed calibrations and increased imprecision of quality control and patient samples when using this product.
Distribution
Worldwide distribution - US Nationwide distribution in the states of AZ, CA, CT, FL, GA, IA, KS, MD, MI, NJ, NM, NY, OH, OK, PA, TN, TX, WA.
Initiated
Voluntary: Firm initiated
Recall number
Z-1363-2020

Terminated Class II Medical devices

Recall started
18 December 2019
Terminated
25 June 2020
Reason
There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology.
Distribution
US Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1233-2020, Z-1231-2020, Z-1232-2020, Z-1230-2020

Terminated Class II Medical devices

Recall started
19 November 2019
Terminated
30 August 2021
Reason
Atellica and ADVIA hsCRP calibrator accuracy has drifted away from the reference materials (ERM-DA470/IFCC), which is causing a high bias on QC and patient sample recovery.
Distribution
Worldwide distribution  US Nationwide distribution in the states of AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, NC, NE, NH, NJ, NM, NV, NY, OH, OR, PA, SC, TN, TX, UT, WA, WY and countries of UK, CA, PH, MX, VN, TW, TH, IN, CO, AE, AR, AU, BD, BE, BG, BR, CL,
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1260-2020, Z-1261-2020

Terminated Class II Medical devices

Recall started
11 October 2019
Terminated
3 May 2021
Reason
On the Atellica CH 930 Analyzer, when scanning barcodes at the module console for Integrated Multisensor Technology (IMT) system fluids (Standard A (Std A) and Standard B (Std B)) for Sodium (Na), Potassium (K), and Chloride (Cl), the system will translate the decimal point separators to commas. This will result in invalid concentration values for the fluids, therefore the system will utilize default nominal values instead of lot specific IMT fluid concentration values for calculation of the calibrations and results for the Na, K, and Cl methods.
Distribution
The products were distributed to the following foreign countries: Argentina, Belgium, Brazil, Denmark, Finland, France, Germany, Greece, Italy, Latvia, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, and Vietnam. No affected products distributed in the United States.
Initiated
Voluntary: Firm initiated
Recall number
Z-0862-2020

Terminated Class II Medical devices

Recall started
23 September 2019
Terminated
6 July 2022
Reason
Potential for calibration error resulting in QC failures after the calibration run with QC and patient results being 5 times higher.
Distribution
Distributed to accounts located in AL AZ AR CA CO FL GA IL IN IA KS KY LA MA MI MN MS NE NV NH NJ NM NY NC OH OR PA SC TN TX UT WA WV DC PR. Foreign distribution to AR AU AT BS BD BE BR BG CA CL CO CW CZ DK EG FI FR DE GR HU IN IR IE IL IT JP KW LV MY MX NL NG NO CN PK PH PL PT QA KR RO RU SA SG SK
Initiated
Voluntary: Firm initiated
Recall number
Z-0581-2020

Terminated Class II Medical devices

Recall started
15 August 2019
Terminated
5 May 2022
Reason
Issues Scanning New Reagent Lot Test Definition on the Atellica IM 1300 Analyzer and Atellica IM 1600 Analyzer SW V 1.19.0 and 1.19.2
Distribution
Nationwide Foreign: Argentina Australia Bangladesh Belgium Brazil Colombia Dominican Republic Finland France Germany Greece Italy Japan Latvia Mexico Netherlands P.R. China Republic Korea Singapore Spain Switzerland Thailand United Kingdom Vietnam
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0204-2020, Z-0205-2020

Terminated Class II Medical devices

Recall started
14 August 2019
Terminated
28 July 2021
Reason
Atellica IM anti-CCP IgG (aCCP) Test Definition (TDef) Mitigation Failure-reagent carryover mitigation for the Testosterone II (TSTII) assay is unable to be completed as defined in the aCCP Test Definition (TDef). The issue occurs on an Atellica IM Analyzer and is isolated to TDef Version 1.0. FOR OUS: Atellica IM anti-CCP IgG (aCCP) and Pregnancy-Associated Plasma Protein-A (PAPP-A) Test Definition (TDef) Mitigation Failure
Distribution
Worldwide distribution - US Nationwide distribution including the states of CA, FL, KY, NH, TX and countries of Austria¿¿¿¿¿¿¿¿ Curacao,¿St¿Eus Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿¿¿ Italy¿¿¿¿¿¿¿¿¿¿ Poland¿¿¿¿¿¿¿¿¿ Slovakia¿¿¿¿¿¿¿ Sp
Initiated
Voluntary: Firm initiated
Recall number
Z-2754-2019

Terminated Class II Medical devices

Recall started
30 July 2019
Terminated
10 June 2022
Reason
Atellica CH 930 Analyzer - Erroneous Indices for Hemolysis and Lipemia in Software versions 1.19.2 and below
Distribution
Worldwide Distribution - US Nationwide Foreign: Argentina Australia Austria Bangladesh Belgium Brazil Bulgaria Canada Chile Colombia Czech Republic Denmark Ecuador Egypt Finland France Germany Greece Hungary India Indonesia Iran Ireland Israel Italy Japan Kuwait Latvia
Initiated
Voluntary: Firm initiated
Recall number
Z-0148-2020

Terminated Class II Medical devices

Recall started
22 July 2019
Terminated
14 February 2025
Reason
Homocysteine Assay May Cause Elevated Results in the Folate Assay
Distribution
Nationwide Foreign: Armenia¿¿¿¿¿¿¿¿ Austria¿¿¿¿¿¿¿¿ Bahrain¿¿¿¿¿¿¿¿ Belgium¿¿¿¿¿¿¿¿ Bosnia¿Herzeg.¿ Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ Egypt¿¿¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Georgia¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿¿¿ Hungary¿¿¿¿¿¿¿¿ Iran¿¿¿¿¿¿¿¿¿¿¿ Ireland¿¿¿¿¿¿¿¿ Israel¿¿¿¿¿¿¿¿¿ Italy¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0829-2020, Z-0830-2020, Z-0831-2020

Terminated Class II Medical devices

Recall started
15 July 2019
Terminated
12 August 2021
Reason
Negative Bias with Lot EA9227.
Distribution
Worldwide Distribution AK AR AZ CA CT FL GA IA ID IL IN KS KY LA
Initiated
Voluntary: Firm initiated
Recall number
Z-2229-2019

Terminated Class II Medical devices

Recall started
10 July 2019
Terminated
28 May 2024
Reason
There is a potential for low discordant progesterone results on a subset of patient samples. A falsely low progesterone result may lead to the consideration for additional progesterone supplementation.
Distribution
Global distribution. US Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2289-2019, Z-2290-2019

Terminated Class II Medical devices

Recall started
27 June 2019
Terminated
27 May 2020
Reason
Iincreased (falsely elevated) Albumin results compared to expected results
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
Z-2341-2019

Terminated Class II Medical devices

Recall started
29 May 2019
Terminated
12 May 2022
Reason
Potential for increased rate of false positive results and/or increased rate of random non-repeatable false positive results.
Distribution
US Nationwide Distribution
Initiated
Voluntary: Firm initiated
Recall number
Z-2135-2019

Terminated Class II Medical devices

Recall started
3 May 2019
Terminated
19 January 2021
Reason
A steady upward trend in blank (u) absorbance was observed
Distribution
Worldwide distribution.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1913-2019, Z-1914-2019

Terminated Class II Medical devices

Recall started
7 March 2019
Terminated
20 August 2020
Reason
There were multiple issues identified in the system software which required an update.
Distribution
The products were distributed to the following US states: AL, AR, AZ, CA, CO, FL, GA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MS, NC, NE, NH, NM, NV, NY, OH, OR, PA, RI, SC, TN, TX, UT, WA, WV, WY, and Puerto Rico. The products were distributed to the following foreign countries: Argentina, Austr
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1300-2019, Z-1301-2019, Z-1299-2019

Terminated Class II Medical devices

Recall started
12 December 2018
Terminated
27 April 2020
Reason
When the Millipore Water Purification Module Progard Pretreatment Packs are used with Dimension Vista Triglyceride assay, patient and QC triglyceride results may be erroneously elevated as a result of contamination.
Distribution
Nationwide domestic distribution. Worldwide foreign distribution.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1015-2019, Z-1014-2019

Terminated Class II Medical devices

Recall started
7 December 2018
Terminated
27 April 2020
Reason
Positive bias anti-thyroglobulin with ADVIA Centaur aTG kit lots ending in 316 and lower and Atellica IM aTG kit lots ending in 317 and lower when compared to the standardization to World Health Organization (WHO) Reference Preparation MRC 65/93 stated in the Instructions for Use (IFU).
Distribution
Nationwide Foreign: Belgium¿¿¿¿¿¿¿¿ Croatia¿¿¿¿¿¿¿¿ Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿¿¿ Ireland¿¿¿¿¿¿¿¿ Italy¿¿¿¿¿¿¿¿¿¿ Poland¿¿¿¿¿¿¿¿¿ Portugal¿¿¿¿¿¿¿ Slovakia¿¿¿¿¿¿¿ Spain¿¿¿¿¿¿¿¿¿¿ Switzerland¿¿¿¿ Turkey¿¿¿¿¿¿¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1234-2019, Z-1235-2019, Z-1236-2019, Z-1233-2019

Terminated Class II Medical devices

Recall started
16 October 2018
Terminated
17 June 2020
Reason
Siemens Healthcare Diagnostics has identified an issue with Dimension Vista software v.3.7 and v.3.8.1 that may result in aliquot well contamination. If a test is cancelled by the operator while the instrument is aliquotting the sample, the Dimension Vista instrument may continue to deliver the cancelled sample or vial contents to the aliquot well(s). Future samples may be assigned to the same aliquot well(s) and become contaminated with the existing contents or overflow of the aliquot well may occur potentially contaminating a surrounding well(s). This issue only occurs when an operator manually cancels a test(s) for calibration, quality control (QC) or patient sample while the instrument is in the process of aliquotting the sample.
Distribution
Nationwide/worldwide distribution.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0616-2019, Z-0617-2019

Terminated Class II Medical devices

Recall started
11 October 2018
Terminated
29 June 2020
Reason
Siemens Healthcare Diagnostics has confirmed that Dimension Vista Lactate Dehydrogenase (LDI) may exhibit an erroneously elevated result when the preceding assay in the reaction cuvette is Lactic Acid (LA). The magnitude of the elevation may be variable. Both quality control and patient samples may be impacted. Incomplete removal of residual lactate dehydrogenase, a component of the LA reagent, has been identified as the cause of the potentially elevated result. A falsely elevated result for lactate dehydrogenase may lead to additional investigations to determine the etiology of tissue damage. Results would be correlated with clinical history and presentation in addition to other diagnostic laboratory testing.
Distribution
Worldwide-domestic nationwide and foreign distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0499-2019

Terminated Class II Medical devices

Recall started
28 September 2018
Terminated
17 June 2020
Reason
Thermal chamber motors have electrical cables with single insulation rather than the required double insulation. There is no exposed current due to the single insulation that could result in a potential electrical shock
Distribution
Worldwide Distribution: US (Nationwide) and countries of: Algeria, Argentina, Australia, Brazil, Canada, China, Columbia, Croatia, Egypt, France, Germany, Great Britain, Greece, Hungary, India, Italy, Japan, Malaysia Mexico, Netherlands, Poland, Portugal, Russia, Saudi Arabia, Slovenia, South Africa
Initiated
Voluntary: Firm initiated
Recall number
Z-0409-2019

Terminated Class II Medical devices

Recall started
26 September 2018
Terminated
24 June 2020
Reason
Multiple Issues Identified in Atellica Solution System Software in V 1.14.2 and lower in: Atellica¿ IM 1300 Analyzer Atellica¿ IM 1600 Analyzer;Atellica¿ CH 930 Analyzer; Atellica¿ Sample Handler Prime
Distribution
Worldwide distributions - US Nationwide and countries of Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia Croatia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Nigeria, Norway, P.R. Chin
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0782-2019, Z-0780-2019, Z-0781-2019, Z-0783-2019

Terminated Class II Medical devices

Recall started
7 September 2018
Terminated
16 November 2020
Reason
There is lot to lot variability for QC and patient results when using the identified reagent cartridge lots.
Distribution
Worldwide - US Nationwide Distributions The products were distributed to the following foreign countries: Argentina, Australia, Bangladesh, Brazil, Canada, Chile, China, Colombia, Germany, Ecuador, Honduras, Indonesia, India, Japan, Republic of Korea, Mexico, Malaysia, Nicaragua, New Zealand, P
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0466-2019, Z-0465-2019

Terminated Class II Medical devices

Recall started
14 August 2018
Terminated
4 September 2020
Reason
The modules may have been shipped without a warning label for potential risk of interference to pacemaker functionality.
Distribution
The products were distributed to the following US states: AL, AR, AZ, CA, CO, CT, DE, FL, GA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NM, NV, NY, OH, OK, PA, SC, TN, TX, VA, WA, and WV. The products were distributed to the following foreign countries: Australia, Aust
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0212-2019, Z-0210-2019, Z-0215-2019, Z-0209-2019, Z-0216-2019, Z-0217-2019, Z-0214-2019, Z-0213-2019, Z-0211-2019

Terminated Class II Medical devices

Recall started
24 July 2018
Terminated
26 May 2020
Reason
A potential bias was identified with certain kits compared to the internal standards.
Distribution
US Nationwide Distribution
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0116-2019, Z-0113-2019, Z-0117-2019, Z-0115-2019, Z-0114-2019

Terminated Class II Medical devices

Recall started
16 July 2018
Terminated
23 June 2020
Reason
Therapeutic levels (1mg/mL and 2mg/mL) of Hydroxocobalamin may interfere with tHb and some of the CO-Ox fractions that are reported on the RAPIDPoint and RAPIDLab Blood Gas systems indicated. This may cause lower than expected values for carboxyhemoglobin (fCOHb) and methemoglobin (fMetHb). A negative interference with fCOHb has the potential to alter the medical assessment of the patient and may withhold necessary follow-up treatment and/or initiate cessation of medication in response to elevated fMetHb levels.
Distribution
Nationwide distribution. Worldwide foreign distribution.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2930-2018, Z-2929-2018, Z-2928-2018, Z-2927-2018

Terminated Class II Medical devices

Recall started
29 June 2018
Terminated
12 August 2021
Reason
Atellica Solution system software (SW) version 1.13 and lower, five (5) behavioral issues were identified: 1. Reagent Lock may not work as intended with Primary Reagent ReadyPacks¿ and Ancillary Packs when more than one (1) lot of specific Reagent kits are loaded on the analyzer at the same time. 2. Sample barcodes may be incorrectly read 3. The Atellica IM 1300 Analyzer and Atellica IM 1600 Analyzer may not run CEA dilutions at 50x and 100x. The Analyzer may post a Sample Integrity Error when 50x or 100x dilutions are ordered for Carcinoembryonic Antigen (CEA). Dilution factors lower than 50x and neat samples are not affected by this behavior. 4. The Atellica CH 930 Analyzer may continue to display the default reporting units after the reporting units have been changed. 5. The Atellica CH 930 Analyzer may not display results for sample if certain assays are configured to auto-dilute results above or below the assay measuring interval.
Distribution
Nationwide Foreign: Australia Austria Belgium Brazil Canada Croatia Czech Republic Denmark France Germany Greece Italy Japan Malaysia Mexico Netherlands Norway Poland Republic Korea Singapore Spain Sweden Switzerland U.A.E. United Kingdom
Initiated
Voluntary: Firm initiated
Recall numbers
Z-0189-2019, Z-0193-2019, Z-0191-2019, Z-0190-2019, Z-0194-2019, Z-0192-2019

Terminated Class II Medical devices

Recall started
19 April 2018
Terminated
24 April 2020
Reason
The affected lots may exhibit inaccuracy for Quality Control and patient samples at the low end of the Analytical Measurement Range. The bias is due to the calibration curve not showing separation between the Level 1 and Level 2 calibrators.
Distribution
Nationwide distribution. Foreign distribution to Argentina, Australia, Brazil, Bahamas, Canada, Germany, India, Japan, Myanmar, New Zealand, Saudi Arabia, Taiwan, and South Africa.
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2181-2018, Z-2182-2018

Terminated Class II Medical devices

Recall started
27 March 2018
Terminated
3 February 2021
Reason
Urea Nitrogen reagent kit demonstrated an increased incidence of Calibration Failures. Results cannot be generated by the system when calibration fails.
Distribution
Nationwide and worldwide
Initiated
Voluntary: Firm initiated
Recall number
Z-2062-2018

Terminated Class II Medical devices

Recall started
21 March 2018
Terminated
12 June 2020
Reason
The diluent may have an incomplete slit on the septum in the cap of the vial. A diluent cap with a defective septum has the potential to cause erroneously elevated results if a sample is autodiluted onboard the system, due to a reduced volume of diluent being pipetted from the vial.
Distribution
The products were distributed to the following US states: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, and WY. The products were distributed to
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2438-2018, Z-2437-2018, Z-2436-2018

Terminated Class III Medical devices

Recall started
12 March 2018
Terminated
2 June 2020
Reason
Incorrect calibrator level listed in qualitative calibration steps
Distribution
PA, MA, TX, ME, UT, FL, KS, NH, KY and Foreign
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1800-2018, Z-1799-2018

Terminated Class II Medical devices

Recall started
26 February 2018
Terminated
12 May 2020
Reason
When more than one immunoassay analyzer is connected to a single solution system, reporting and conversion factors may not be applied to all analyzers
Distribution
FL and France Spain Sweden United Kingdom Germany
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1588-2018, Z-1586-2018, Z-1587-2018

Terminated Class II Medical devices

Recall started
21 February 2018
Terminated
16 May 2019
Reason
Upon dilution, some patient samples may exhibit over-recovery outside the representative data provided in the assay instructions for use.
Distribution
US Nationwide, and the following countries: Albania, Angola, Argentina, Armenia, Australia, Austria, Bahrain, Bangladesh, Belgium, Bosnia Herzegovina, Brazil, Bulgaria, Cambodia, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, F
Initiated
Voluntary: Firm initiated
Recall number
Z-1486-2018

Terminated Class II Medical devices

Recall started
30 January 2018
Terminated
16 May 2019
Reason
May produce erroneously low results from specific well sets.
Distribution
Worldwide Distribution - USA (nationwide) and to the following countries: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Italy, Japan, Norway, Portugal, Slovakia, Slovenia, South Korea, Spain, Switzerland
Initiated
Voluntary: Firm initiated
Recall number
Z-1540-2018

Terminated Class II Medical devices

Recall started
2 January 2018
Terminated
10 February 2023
Reason
Concentrations for the level of biotin that does not interfere is not currently listed in the instruction for use for the Dimension Vista CTNI, Dimension Vista MMB, Dimension Sirolimus, ADVIA Centaur FOL, ADVIA Centaur aHBcM and the following IMMULITE assays, 3gAllergy Specific IgE, anti-HBc, BR-MA (CA15-3), CEA, Folic Acid, Gastrin, OM-MA (CA125), Thyroglobulin, and Vitamin B12, and these assays are susceptible to interference from biotin.
Distribution
Nationwide and Canada, Mexico, and Thailand
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1691-2018, Z-1680-2018, Z-1677-2018, Z-1682-2018, Z-1688-2018, Z-1681-2018, Z-1675-2018, Z-1669-2018, Z-1672-2018, Z-1690-2018, Z-1678-2018, Z-1679-2018 and 12 more

Ongoing Class II Medical devices

Recall started
18 December 2017
Reason
In certain scenarios the ADVIA Centaur CP, XP and XPT immunoassay analyzers may exhibit reduced dilution recovery or become inoperable when used with Multi-Diluent 15 and certain lots of BNP and TSH3RUL Assays.
Distribution
Distributed in the following U.S. states: AL, CA, DE, GA, IA, IL, IN, KY, MA, MI, MS, MT, NC, ND, NJ, NM, NV, NY, OH, PA, RI, TN, TX, VA, WA, WV, WY and Puerto Rico. Distributed in the following OUS countries: Australia Belgium¿¿¿¿¿¿¿¿ Canada Chile France¿¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-2054-2018, Z-2053-2018

Terminated Class II Medical devices

Recall started
14 December 2017
Terminated
3 December 2020
Reason
Calibration failure - confirmed a positive bias with LIPL lot FB8109 when compared to other Dimension LIPL lots. Lot FB8109 is not meeting Siemens internal specifications for lot-to-lot limits.
Distribution
Domestic and Foreign consignees
Initiated
Voluntary: Firm initiated
Recall number
Z-1796-2018

Terminated Class II Medical devices

Recall started
27 November 2017
Terminated
19 April 2019
Reason
Lot J1 of the Syva¿ EMIT¿ 2000 Theophylline Assay, when run on a Beckman AU Clinical Chemistry System, may exhibit increased imprecision for commercially available controls and for patient samples.
Distribution
US Nationwide Distribution
Initiated
Voluntary: Firm initiated
Recall number
Z-1946-2018

Terminated Class II Medical devices

Recall started
9 November 2017
Terminated
8 June 2020
Reason
An increase in the number of failed calibration events or negative bias with Quality Control (QC) and patient samples when using Dimension Vista LOCI 8 Calibrator lot 7CD076 to calibrate Estradiol (E2) Assay.
Distribution
Worldwide Distribution: US (nationwide) and countries of: Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Slovakia, Spain and Switzerland.
Initiated
Voluntary: Firm initiated
Recall number
Z-1184-2018

Terminated Class II Medical devices

Recall started
17 October 2017
Terminated
4 November 2019
Reason
The BC Thrombin Reagent kit lot 46751 (contains Thrombin Reagent lot 517468) and kit lot 47184 (contains Thrombin Reagent lot 517469) produce unexpected prolonged Thrombin Time (TT) results for expected normal samples, and may recover above the upper limit of normal (< 21 sec.) as stated within the IFU (Instruction For Use).
Distribution
Worldwide distribution. US nationwide, Austria, Belgium, Bosnia-Herzegovina, Croatia, Finland, France (incl. Guadeloupe, Martinique, Reunion, French Guinea overseas departments), Germany, Greece, Hungary, Italy, Kazakhstan, Macedonia, Latvia, Poland, Portugal, Qatar, Russian Federation, Saudi Arabi
Initiated
Voluntary: Firm initiated
Recall number
Z-0827-2018

Terminated Class II Medical devices

Recall started
28 July 2017
Terminated
3 April 2019
Reason
Siemens has identified an issue when scanning the 20 barcode for the Master Curve Card (MCC) with ADVIA Centaur systems T3 kit lots ending in 198 on the ADVIA Centaur XPT system.
Distribution
Worldwide Distribution - US Distribution.
Initiated
Voluntary: Firm initiated
Recall number
Z-0720-2018

Terminated Class II Medical devices

Recall started
29 June 2017
Terminated
23 April 2020
Reason
Various assays used to measure different chemical levels in blood, urine, or cerebrospinal fluid may interfere with the drugs sulfasalazine and/or sulfapyridine causing falsely elevated or falsely depressed results.
Distribution
Distributed in all 50 U.S. states, the District of Columbia, Guam, and Puerto Rico. Distributed in 108 foreign countries: Afghanistan Bolivia Albania¿¿¿¿¿¿¿¿ Algeria¿¿¿¿¿¿¿¿ Angola ARGENTINA Armenia AUSTRALIA Austria¿¿¿¿¿¿¿¿ Azerbaijan Bahamas Bahrain¿¿¿¿¿¿¿¿ Bangladesh¿¿¿¿¿ Belarus¿¿
Initiated
Voluntary: Firm initiated
Recall numbers
Z-1647-2018, Z-1660-2018, Z-1654-2018, Z-1646-2018, Z-1651-2018, Z-1648-2018, Z-1652-2018, Z-1649-2018, Z-1659-2018, Z-1662-2018, Z-1657-2018, Z-1661-2018 and 5 more

Terminated Class II Medical devices

Recall started
7 June 2017
Terminated
8 May 2019
Reason
Siemens Healthcare Diagnostics has confirmed a negative bias for ADVIA Centaur Enhanced Estradiol (eE2) on the ADVIA Centaur, ADVIA Centaur XP and ADVIA Centaur XPT systems when calibrating with Calibrator 30 kit lots ending in 21 (C3021) as compared to Calibrator 30 kit lots ending in 20 (C3020).
Distribution
US and OUS.
Initiated
Voluntary: Firm initiated
Recall number
Z-0515-2018

Terminated Class II Medical devices

Recall started
26 August 2015
Terminated
24 March 2020
Reason
Software Issues.
Distribution
Worldwide distribution - US Nationwide and countries of Japan, Germany, Belgium, France, Italy, Slovakia, Bahamas, United Kingdom and Mexico.
Initiated
Voluntary: Firm initiated
Recall number
Z-1195-2019

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.